Giovanni Cianchetta

Giovanni Cianchetta

Agios Pharmaceuticals, Inc. - / United States
Natural Sciences / Chemical Sciences
AD Scientific Index ID: 4978782
person_outline Giovanni Cianchetta's MOST POPULAR ARTICLES
1-) AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 MutationsAG-221 Therapy for IDH2-Mutant AML K Yen, J Travins, F Wang, MD David, E Artin, K Straley, A Padyana, ... Cancer discovery 7 (5), 478-493, 2017 3482017
2-) Discovery of AG-120 (Ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers J Popovici-Muller, RM Lemieux, E Artin, JO Saunders, FG Salituro, ... ACS medicinal chemistry letters 9 (4), 300-305, 2018 2952018
3-) Small Molecule Activation of PKM2 in Cancer Cells Induces Serine Auxotrophy C Kung, J Hixon, S Choe, K Marks, S Gross, E Murphy, B DeLaBarre, ... Chemistry & Biology 19 (9), 1187-1198, 2012 1742012
4-) Structure and inhibition mechanism of the catalytic domain of human squalene epoxidaseAK Padyana, S Gross, L Jin, G Cianchetta, R Narayanaswamy, F Wang, ...Nature communications 10 (1), 97, 20191202019
5-) AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiencyC Kung, J Hixon, PA Kosinski, G Cianchetta, G Histen, Y Chen, C Hill, ...Blood, The Journal of the American Society of Hematology 130 (11), 1347-1356, 20171192017